Chinese drug start-ups poised for 2025 profits, in industry milestone

Chinese drug start-ups poised for 2025 profits, in industry milestone

Innovent likely to post a first-half net profit of US$36.4 million, and BeOne’s first-half net profit is expected to come in at US$42 million.

Chinese Biotech Startups Hit Profit Milestone in 2025

Chinese biotech companies Innovent, BeOne, and Akeso have earned billions of yuan from licensing drug candidates to multinational partners for overseas development. A pair of mainland Chinese biotechnology companies listed in Hong Kong is expected to make a profit this year, as their income from new pharmaceuticals finally surpasses their research and development (R&D) and marketing expenses. In a report released on July 16, Tony Ren, head of As…